Keith Winfrey
Internal Medicine · New Orleans, LANPI 1649212382
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Exact Sciences accounts for 71.3% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $4,746, more than ten times the $86 reported in 2019. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $80.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$5K
- Gilead$492
- Lilly USA, LLC$364
- Novo Nordisk$132
- Regeneron Healthcare Solutions, Inc.$122
- Global Blood Therapeutics, Inc.$118
- plus $639 from 14 others
Across 3 payments — averaging $28,963 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orasure Technologies Inc.$87K
What the payments were for
- Consulting fees$2,80043%
- Speaking & faculty fees$87513%
- Travel & lodging$4327%
- Food & beverage$2,40737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 26 | $4,647 |
| Gilead | 10 | $492 |
| Lilly USA, LLC | 6 | $364 |
| Novo Nordisk | 2 | $132 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Global Blood Therapeutics, Inc. | 3 | $118 |
| Medtronic | 1 | $106 |
| Merck | 6 | $88 |
| Organon | 5 | $82 |
| Pfizer | 4 | $70 |
| Hologic Sales And Service, LLC | 3 | $47 |
| Sanofi Pasteur Inc. | 3 | $43 |
| Phadia US Inc. | 2 | $40 |
| Sanofi | 2 | $34 |
| Regeneron | 1 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| GSK | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Qiagen, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cologuard Collection Kit$3,313
- The Cologuard Plus Collection Kit$990
- Epclusa$247
- DUPIXENT$122
- ZEPBOUND$122
- RYBELSUS$117
- MOUNJARO$111
- VenaSeal$106
How this compares
$6,514 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 38 | $56,654 |
| OzempicSemaglutide | 44 | $55,027 |
| MounjaroTirzepatide | 45 | $50,446 |
| JardianceEmpagliflozin | 71 | $47,760 |
| JanuviaSitagliptin Phosphate | 19 | $29,866 |
| EliquisApixaban | 40 | $26,451 |
| TradjentaLinagliptin | 20 | $17,256 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $8,601 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,997 |
| MyrbetriqMirabegron | 11 | $6,520 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,368 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $5,053 |
| Nifedipine ErNifedipine | 64 | $2,040 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 82 | $1,853 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $1,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $30 | $65,01791 claims |
| GileadVemlidy | $492 | $56,65438 claims |
| Novo NordiskOzempic | $132 | $55,02744 claims |
| Lilly USA, LLCMounjaro | $364 | $50,44645 claims |
| MerckJanuvia | $88 | $29,86619 claims |
| PfizerEliquis | $70 | $26,45140 claims |
| GSKAnoro Ellipta | $15 | $6,36813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- Steven DeitelzweigNew Orleans$939K
- Daniel EnglertNew Orleans$74K
- Jordan GrahamNew Orleans$25K
- Pavan ChavaNew Orleans$24K
- Susan KaramNew Orleans$22K
- Arti ThanguduNew Orleans$20K
- David BrownNew Orleans$17K
- Peter PantlinNew Orleans$13K
- Genevieve MarongeNew Orleans$12K
- Samiullah ArshadNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.